InMed Pharmaceuticals (IN.T) has filed clinical trial applications (CTAs) in Austria, Israel and Serbia as part of a phase 2 clinical trial of INM-755, the Company’s cannabinol cream used…
InMed Pharmaceuticals
InMed Pharmaceutical’s (IN.T) IntegraSyn™ cannabinoid manufacturing approach has achieved a level of 2 grams per liter (g/L), marking a significant milestone for the commercialization of IntegraSyn™. “We are very…
Inmed Pharmaceuticals (IN.T) filed a patent co-operation treaty (PCT) application relating to the potential for cannabinoids to prevent neuron damage associated with glaucoma. The patent application is called “Compositions…
In the spirit of ‘where are they now’ day comes another in my trilogy of companies I used to write about a lot, that I stopped writing about as…